tetano
Editor, Senior Moderator
iScience
. 2021 Sep 15;24(10):103131.
doi: 10.1016/j.isci.2021.103131. eCollection 2021 Oct 22.
Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza
Meito Shibuya[SUP] 1 2 3 [/SUP], Shigeyuki Tamiya[SUP] 1 2 3 [/SUP], Atsushi Kawai[SUP] 1 2 3 [/SUP], Toshiro Hirai[SUP] 1 2 3 [/SUP], Mark S Cragg[SUP] 4 [/SUP], Yasuo Yoshioka[SUP] 1 2 3 5 6 [/SUP]
Affiliations
Abstract
Current influenza vaccines do not typically confer cross-protection against antigenically mismatched strains. To develop vaccines conferring broader cross-protection, recent evidence indicates the crucial role of both cross-reactive antibodies and viral-specific CD4[SUP]+[/SUP] T cells; however, the precise mechanism of cross-protection is unclear. Furthermore, adjuvants that can efficiently induce cross-protective CD4[SUP]+[/SUP] T cells have not been identified. Here we show that CpG oligodeoxynucleotides combined with aluminum salts work as adjuvants for influenza vaccine and confer strong cross-protection in mice. Both cross-reactive antibodies and viral-specific CD4[SUP]+[/SUP] T cells contributed to cross-protection synergistically, with each individually ineffective. Furthermore, we found that downregulated expression of Fcγ receptor IIb on alveolar macrophages due to IFN-γ secreted by viral-specific CD4[SUP]+[/SUP] T cells improves the activity of cross-reactive antibodies. Our findings inform the development of optimal adjuvants for vaccines and how influenza vaccines confer broader cross-protection.
Keywords: Biological sciences; Immune response; Immunology.
. 2021 Sep 15;24(10):103131.
doi: 10.1016/j.isci.2021.103131. eCollection 2021 Oct 22.
Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza
Meito Shibuya[SUP] 1 2 3 [/SUP], Shigeyuki Tamiya[SUP] 1 2 3 [/SUP], Atsushi Kawai[SUP] 1 2 3 [/SUP], Toshiro Hirai[SUP] 1 2 3 [/SUP], Mark S Cragg[SUP] 4 [/SUP], Yasuo Yoshioka[SUP] 1 2 3 5 6 [/SUP]
Affiliations
- PMID: 34622175
- PMCID: PMC8482522
- DOI: 10.1016/j.isci.2021.103131
Abstract
Current influenza vaccines do not typically confer cross-protection against antigenically mismatched strains. To develop vaccines conferring broader cross-protection, recent evidence indicates the crucial role of both cross-reactive antibodies and viral-specific CD4[SUP]+[/SUP] T cells; however, the precise mechanism of cross-protection is unclear. Furthermore, adjuvants that can efficiently induce cross-protective CD4[SUP]+[/SUP] T cells have not been identified. Here we show that CpG oligodeoxynucleotides combined with aluminum salts work as adjuvants for influenza vaccine and confer strong cross-protection in mice. Both cross-reactive antibodies and viral-specific CD4[SUP]+[/SUP] T cells contributed to cross-protection synergistically, with each individually ineffective. Furthermore, we found that downregulated expression of Fcγ receptor IIb on alveolar macrophages due to IFN-γ secreted by viral-specific CD4[SUP]+[/SUP] T cells improves the activity of cross-reactive antibodies. Our findings inform the development of optimal adjuvants for vaccines and how influenza vaccines confer broader cross-protection.
Keywords: Biological sciences; Immune response; Immunology.